JCN Newswire
TOKYO, Nov 7, 2024 – (JCN Newswire) – Utilizing proprietary generative AI technology, NEC Bio has successfully modified T cell receptors (TCRs) to increase their efficacy. This achievement marks a major step forward in drug development and personalized medicine since prediction and engineering of TCR sequences that are able to bind to specific target sequences remains a major challenge in the field…
Read More
NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting
Blythe Mcnaught
00:30
TOKYO, Nov 7, 2024 – (JCN Newswire) – Utilizing proprietary generative AI technology, NEC Bio has successfully modified T cell receptors (TCRs) to increase their efficacy. This achievement marks a major step forward in drug development and personalized medicine since prediction and engineering of TCR sequences that are able to bind to specific target sequences
